As Roche pre­pares to take a kid­ney dis­ease drug in­to PhI­II, Io­n­is flesh­es out the da­ta

A few days af­ter Bay­er end­ed its col­lab­o­ra­tion with Io­n­is, the biotech is trudg­ing for­ward with an­oth­er pro­gram it sold to Roche over the sum­mer.

Io­n­is re­vealed new de­tails on a Phase II tri­al for IO­N­IS-FB-LRx, an an­ti­sense pro­gram de­signed to treat im­munoglob­u­lin A (IgA) nephropa­thy, which hit its pri­ma­ry end­point ear­li­er this year. The drug is slat­ed to en­ter Phase III in the first half of 2023, with Roche — hav­ing ac­quired the rights in Ju­ly — head­ing up all clin­i­cal de­vel­op­ment ef­forts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER